Inlexzo gets the nod in BCG-unresponsive non-muscle invasive bladder cancer, but the group has bigger plans.

But first it will need to identify the optimal dose in first-line small-cell lung cancer.

So far the data, with a Car-T Legend licensed to Novartis, lag antibody approaches.

The latest projects newly into human trials include BNT3212.

But results come from a curated dataset, with no in-trial comparator.

Global data are in the same ballpark as Chinese results presented earlier this year.

A common mutation comes into play for PRMT5 inhibition.

Tolerability could decide first-line therapy in EGFRm disease.

Early data with IDE849 look better those with Zai’s zocilurtatug pelitecan.

Investors now have more reasons to doubt Harmoni's ability to back US approval.